Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy

NCT05180006 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

33

Enrollment

OTHER

Sponsor class

Stopped Abandon of the partner, ROCHE

Conditions

Breast Cancer

Interventions

DRUG: Atezolizumab Injection
DRUG: Bevacizumab
DRUG: Pertuzumab
DRUG: Trastuzumab

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Collaborators

Hoffmann-La Roche